Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Welte

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Sexually Transmitted Infections|October 24, 2003
A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatisR Welte, M Kretzschmar, J A R van den Hoek, et al.
Sexually Transmitted Infections|March 2, 2002
Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approachesM J Postma, R Welte, J A R van den Hoek, et al.
Vaccine|September 25, 2001
Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination programJ M Bos, H C Rümke, R Welte, et al.
Health Services Management Research|May 13, 2022
Association between asthma control and healthcare costs: Results from a German linked data studyThomas Wilke, Hartmut Timmermann, Sabrina Mueller, et al.
Vaccine|January 22, 2019
The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in GermanyStefan Scholz, Florian Koerber, Kinga Meszaros, et al.
Sexually Transmitted Diseases|October 18, 2000
Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approachR Welte, M Kretzschmar, R Leidl, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerationsM J Postma, J M Bos, R Welte, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 11, 1999
[Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment]M J Postma, R Welte, J A van den Hoek, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 13, 1999
[Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women]M J Postma, R Welte, J A van den Hoek, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 14, 2001
Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia TrachomatisM J Postma, R Welte, J A van den Hoek, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Sexually Transmitted Infections|October 24, 2003
A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatisR Welte, M Kretzschmar, J A R van den Hoek, et al.
Sexually Transmitted Infections|March 2, 2002
Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approachesM J Postma, R Welte, J A R van den Hoek, et al.
Vaccine|September 25, 2001
Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination programJ M Bos, H C Rümke, R Welte, et al.
Health Services Management Research|May 13, 2022
Association between asthma control and healthcare costs: Results from a German linked data studyThomas Wilke, Hartmut Timmermann, Sabrina Mueller, et al.
Vaccine|January 22, 2019
The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in GermanyStefan Scholz, Florian Koerber, Kinga Meszaros, et al.
Sexually Transmitted Diseases|October 18, 2000
Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approachR Welte, M Kretzschmar, R Leidl, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 29, 2004
Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerationsM J Postma, J M Bos, R Welte, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 11, 1999
[Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment]M J Postma, R Welte, J A van den Hoek, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 13, 1999
[Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women]M J Postma, R Welte, J A van den Hoek, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 14, 2001
Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia TrachomatisM J Postma, R Welte, J A van den Hoek, et al.
Pageof 3